TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29358500

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus Pegylated Interferon alfa-2b
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus Ipilimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29358950

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 230

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 230
Study: 29358961

Group type: EXPERIMENTAL
Intervention: Verum acupuncture (VA) group 1 (3 times weekly for 4 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Verum acupuncture (VA) group 2 (twice weekly for 4 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham acupuncture group (SA; twice weekly for 4 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All groups (including healthy controls)
Number of subjects: 30
Study: 29359452

Group type: EXPERIMENTAL
Intervention: Balloon undilatable CTOs
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: High pressure balloon inflations
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Rotational atherectomy
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Laser
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Cutting balloons
Number of subjects: 415
Study: 29359461

Group type: EXPERIMENTAL
Intervention: Nutritional and physical performance parameters
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Hypoalbuminaemia
Number of subjects: 517
Study: 29360184

Group type: EXPERIMENTAL
Intervention: Single-agent post-transplantation cyclophosphamide (PTCy) for MBM grafts
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: PTCy, tacrolimus, and mycophenolate mofetil (MMF) 30 mg/kg for MPBSC grafts
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: PTCy, tacrolimus, and MMF 45 mg/kg for MMG grafts
Number of subjects: 200

Group type: COMPARATOR
Intervention: Combination arms (PTCy, tacrolimus, and MMF)
Number of subjects: 200
Study: 29360291

Group type: EXPERIMENTAL
Intervention: Cranial Electrotherapy Stimulation (CES) for 20 minutes
Number of subjects: 50
Study: 29360414

Group type: EXPERIMENTAL
Intervention: Escalated BEACOPP with or without rituximab
Number of subjects: 782

Group type: COMPARATOR
Intervention: ABVD
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: Radiotherapy after chemotherapy
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: Overall survival of all patients
Number of subjects: 782
Study: 29360462

Group type: EXPERIMENTAL
Intervention: Large SPSS (L-SPSS, ≥8 mm)
Number of subjects: 1729

Group type: EXPERIMENTAL
Intervention: Small SPSS (S-SPSS, <8 mm)
Number of subjects: 1729

Group type: COMPARATOR
Intervention: Without SPSS (W-SPSS)
Number of subjects: 1729

Group type: EXPERIMENTAL
Intervention: SPSS (both L-SPSS and S-SPSS)
Number of subjects: 1729

Group type: EXPERIMENTAL
Intervention: SPSS with MELD scores of 6-9
Number of subjects: 1729

Group type: EXPERIMENTAL
Intervention: SPSS with MELD scores of 10-13
Number of subjects: 1729

Group type: EXPERIMENTAL
Intervention: SPSS with MELD scores of 14 or more
Number of subjects: 1729
Study: 29360526

Group type: EXPERIMENTAL
Intervention: Ibrutinib therapy, short-term, dosage and duration not specified
Number of subjects: 0
Study: 29360987

Group type: EXPERIMENTAL
Intervention: AtriClip PRO device for left atrial appendage (LAA) occlusion
Number of subjects: 40
Study: 29361097

Group type: EXPERIMENTAL
Intervention: 4.8 g/day multimatrix mesalamine for 8 weeks (induction period)
Number of subjects: 717

Group type: EXPERIMENTAL
Intervention: 2.4 g/day multimatrix mesalamine for 12 additional months (maintenance period)
Number of subjects: 717

Group type: EXPERIMENTAL
Intervention: Fluctuating between complete and partial remission during maintenance treatment
Number of subjects: 717
Study: 29361134

Group type: EXPERIMENTAL
Intervention: Targeted capture sequencing
Number of subjects: 222
Study: 29361268

Group type: EXPERIMENTAL
Intervention: Ventral gamma capsulotomy
Number of subjects: 55
Study: 29361435

Group type: EXPERIMENTAL
Intervention: SGM-101 (10 mg) administered intravenously 4 days before surgery
Number of subjects: 26
Study: 29361444

Group type: EXPERIMENTAL
Intervention: Functional incomplete revascularization (IR) group (rFSS ≥1)
Number of subjects: 385

Group type: COMPARATOR
Intervention: Functional complete revascularization (CR) group (rFSS = 0)
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Residual functional SYNTAX score (rFSS)
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Combined anatomic and physiological scoring system (rFSS)
Number of subjects: 385
Study: 29361470

Group type: EXPERIMENTAL
Intervention: Prexasertib 105 mg/m administered intravenously
Number of subjects: 28
Study: 29361484

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 29361843

Group type: EXPERIMENTAL
Intervention: Online advertising (Facebook advertisements)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Community fairs
Number of subjects: 406

Group type: COMPARATOR
Intervention: Direct mail
Number of subjects: 406

Group type: COMPARATOR
Intervention: Periodicals
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Online advertising targeting general population
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Online advertising targeting under-represented populations
Number of subjects: 406
Study: 29361917

Group type: EXPERIMENTAL
Intervention: M1 macrophages infiltration in tumor islets
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Total M2 macrophages infiltration in tumor (islets and stroma)
Number of subjects: 80
Study: 29361934

Group type: EXPERIMENTAL
Intervention: SMS text message adherence support intervention for high blood pressure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29362233

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 29362251

Group type: EXPERIMENTAL
Intervention: Evaluation of key performance measures such as time to first ECG, receipt of troponin testing, receipt of reperfusion therapy for ST segment elevation ACS, provision of angiography for troponin-positive patients.
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Assessment of secondary outcomes including revisit to ED and rehospitalisation within 30 days.
Number of subjects: 10000
Study: 29362665

Group type: EXPERIMENTAL
Intervention: Paricalcitol (Vitamin D receptor activation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29362685

Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine fixed-dose combination tablets (ASAQ Winthrop®)
Number of subjects: 480
Study: 29362724

Group type: EXPERIMENTAL
Intervention: Suboptimal antiretroviral therapy adherence (<100%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimal antiretroviral therapy adherence (≥100%)
Number of subjects: 0
Study: 29363050

Group type: EXPERIMENTAL
Intervention: Lamotrigine pharmacokinetics in children aged 1.7 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lamotrigine pharmacokinetics in older adults (> 65 years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Allometric pharmacokinetic model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comedications (Carbamazepine, Phenytoin, Valproic Acid)
Number of subjects: 0
Study: 29363235

Group type: EXPERIMENTAL
Intervention: E7777 (6, 12, and 9 μg/kg/day)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: E7777 (9 μg/kg/day)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: E7777
Number of subjects: 13
Study: 29363250

Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg once daily
Number of subjects: 28
Study: 29363343

Group type: EXPERIMENTAL
Intervention: Fevipiprant (QAW039)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29363446

Group type: EXPERIMENTAL
Intervention: Tetravalent dengue DNA vaccine (TVDV) formulated in Vaxfectin
Number of subjects: 0
Study: 29363651

Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RIC) consisting of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuffs on bilateral upper limbs twice a day for 90 days.
Number of subjects: 165
Study: 29363760

Group type: EXPERIMENTAL
Intervention: Synchrony traces (2D-3D inference method)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Calypso traces (2D-3D inference method)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Gaussian PDF method
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Kalman filter
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Interdimensional correlation method
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Arbitrary-shape PDF method
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Tracking error
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Interdimensional correlation and BPI
Number of subjects: 53
Study: 29364548

Group type: EXPERIMENTAL
Intervention: Micafungin 100 mg/d (adults) and 2 mg/kg/d (paediatrics)
Number of subjects: 685

Group type: COMPARATOR
Intervention: L-AmB 3 mg/kg/d
Number of subjects: 685

Group type: EXPERIMENTAL
Intervention: Micafungin 100 mg/d and 150 mg/d
Number of subjects: 685

Group type: COMPARATOR
Intervention: Caspofungin 70 mg/d followed by 50 mg/d
Number of subjects: 685
Study: 29364592

Group type: EXPERIMENTAL
Intervention: Nondirected uterus donation
Number of subjects: 6
Study: 29364886

Group type: EXPERIMENTAL
Intervention: VRC01LS intravenous (IV) infusion at 20 mg/kg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: VRC01LS intravenous (IV) infusion at 40 mg/kg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: VRC01LS intravenous (IV) administration at 5 mg/kg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: VRC01LS subcutaneous (SC) administration at 5 mg/kg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: VRC01LS IV dose range of 5-40 mg/kg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: VRC01LS
Number of subjects: 37
Study: 29364998

Group type: EXPERIMENTAL
Intervention: Radiological signs of pulmonary congestion (assessed by a radiological score on digital chest X-rays) before the spontaneous breathing trial (SBT)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Radiological findings of pulmonary congestion
Number of subjects: 170
Study: 29365099

Group type: EXPERIMENTAL
Intervention: Teriparatide 20 µg administered by subcutaneous injection daily for 104 weeks
Number of subjects: 20
Study: 29366329

Group type: EXPERIMENTAL
Intervention: Immediate magnetic resonance imaging (MRI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29366510

Group type: EXPERIMENTAL
Intervention: Targeted treatment based on molecular alterations identified from tumor biopsy
Number of subjects: 0
Study: 29366580

Group type: EXPERIMENTAL
Intervention: Urinary biomarkers (neutrophil gelatinase-associated lipocalin, midkine, interleukin 6)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Neutrophil gelatinase-associated lipocalin positive/RIFLE-positive
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Midkine-positive/RIFLE-positive
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Neutrophil gelatinase-associated lipocalin or interleukin 6 positive
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Single-biomarker-positive subclinical AKI
Number of subjects: 200
Study: 29366960

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000-1250 mg/kg over 30-60 min i.v infusion)
Number of subjects: 285
Study: 29367186

Group type: EXPERIMENTAL
Intervention: Facebook advertising campaign
Number of subjects: 621

Group type: COMPARATOR
Intervention: Traditional recruitment methods
Number of subjects: 621
Study: 29367212

Group type: EXPERIMENTAL
Intervention: Cardiosphere-derived cells (CDCs) infusion
Number of subjects: 101

Group type: COMPARATOR
Intervention: Staged palliation alone (Control)
Number of subjects: 101
Study: 29367268

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 1008
Study: 29367293

Group type: EXPERIMENTAL
Intervention: T2 magnetic resonance (T2MR) assay
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blood culture
Number of subjects: 0
Study: 29368166

Group type: EXPERIMENTAL
Intervention: Long-term physical activity (exercise within the calculated training pulse) for 8 months
Number of subjects: 98

Group type: COMPARATOR
Intervention: Baseline measurement of serum sRAGE levels
Number of subjects: 98
Study: 29368271

Group type: EXPERIMENTAL
Intervention: Anti-CCP2 antibody positive patients (Gp1-3)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Increasing anti-CCP2 titer groups (Gp1-3)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Patients with low DXR-BMD
Number of subjects: 149

Group type: COMPARATOR
Intervention: Anti-CCP2 antibody negative patients
Number of subjects: 149
Study: 29368313

Group type: EXPERIMENTAL
Intervention: Bedside transthoracic echocardiography (TTE) with a bubble study to detect PFO
Number of subjects: 202
Study: 29368632

Group type: EXPERIMENTAL
Intervention: suPAR levels in patients with CAP
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: syndecan-4 levels in patients with CAP
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: suPAR for predicting mortality in SCAP
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: syndecan-4 for predicting mortality in SCAP
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Combination of suPAR and syndecan-4 with Pneumonia Severity Index
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: suPAR ≥10.22 ng/mL and syndecan-4 ≤6.68 ng/mL
Number of subjects: 282
Study: 29368656

Group type: EXPERIMENTAL
Intervention: Workplace-based clinical supervision
Number of subjects: 70
Study: 29368673

Group type: EXPERIMENTAL
Intervention: Health care services costs
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Overall 6-month cost
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Lost productive hours costs
Number of subjects: 150
Study: 29369091

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 2.5 µg·kg
Number of subjects: 280

Group type: COMPARATOR
Intervention: Oral pentobarbital 5 mg·kg
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 1 µg·kg (rescue sedation)
Number of subjects: 280
Study: 29369664

Group type: EXPERIMENTAL
Intervention: Escitalopram, Duloxetine, or Cognitive Behavior Therapy (CBT)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Residual depressive symptoms on the Hamilton Depression Rating Scale
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Not having a comorbid anxiety disorder diagnosis at study baseline
Number of subjects: 94
Study: 29369665

Group type: EXPERIMENTAL
Intervention: Distress Intolerance (DI)
Number of subjects: 256
Study: 29369678

Group type: EXPERIMENTAL
Intervention: Meaning salience
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Global meaning and purpose
Number of subjects: 80
Study: 29370183

Group type: EXPERIMENTAL
Intervention: Oral anticoagulant (OAC) resumption after ICH
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Timing of OAC resumption
Number of subjects: 228

Group type: COMPARATOR
Intervention: Neurosurgery respondents' preference for OAC resumption timing
Number of subjects: 228
Study: 29370218

Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla-300)
Number of subjects: 1689

Group type: COMPARATOR
Intervention: Insulin glargine 100 U/mL (Gla-100)
Number of subjects: 1689
Study: 29370229

Group type: EXPERIMENTAL
Intervention: Anticoagulants (ACs) with or without antiplatelet (AP) therapy
Number of subjects: 28628

Group type: COMPARATOR
Intervention: No antithrombotic therapy
Number of subjects: 28628
Study: 29370428

Group type: EXPERIMENTAL
Intervention: Online haemodiafiltration (OL-HDF)
Number of subjects: 33

Group type: COMPARATOR
Intervention: High-flux haemodialysis (HF-HD)
Number of subjects: 33
Study: 29370708

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 29370795

Group type: EXPERIMENTAL
Intervention: Postpartum weight retention intervention including six weeks of interactive daily health texting, exercise assistance with baby carrier, home exercise program, pedometer provision, two live healthy eating and baby feeding workshops, and two 45-min home visits over one year
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Postpartum weight retention intervention
Number of subjects: 17
Study: 29370811

Group type: EXPERIMENTAL
Intervention: 5 mg prednisolone daily added to standard of care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matching placebo added to standard of care
Number of subjects: 0
Study: 29370824

Group type: EXPERIMENTAL
Intervention: Home-based physical activity incentive program (HB-PAI) over 6 months
Number of subjects: 84

Group type: COMPARATOR
Intervention: Traditional medical care over 12 months (Control Group)
Number of subjects: 84
Study: 29371177

Group type: EXPERIMENTAL
Intervention: Automated mobile phone-based personalized daily step goals
Number of subjects: 64

Group type: COMPARATOR
Intervention: Constant step goals of 10,000 steps per day (active control)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Comparison between intervention and control
Number of subjects: 64
Study: 29371241

Group type: EXPERIMENTAL
Intervention: Clinical Decision Support (CDS) tool
Number of subjects: 31579

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 31579
Study: 29371263

Group type: COMPARATOR
Intervention: Naturalistic study with longitudinal follow-up
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Computational models based on Bayesian statistics
Number of subjects: 1000
Study: 29371473

Group type: EXPERIMENTAL
Intervention: Cisplatin, Docetaxel, and Erlotinib
Number of subjects: 50
Study: 29371475

Group type: EXPERIMENTAL
Intervention: Everolimus, 10 mg daily
Number of subjects: 2
Study: 29371864

Group type: EXPERIMENTAL
Intervention: Loratadine tablets
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 29372071

Group type: EXPERIMENTAL
Intervention: Randomly generated, customised prompts delivered by Microsoft Outlook
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Education session
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prompts delivered by Microsoft Outlook
Number of subjects: 0

Group type: COMPARATOR
Intervention: Education alone
Number of subjects: 0
Study: 29372135

Group type: EXPERIMENTAL
Intervention: Two-level TDR
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: One-level TDR
Number of subjects: 599

Group type: COMPARATOR
Intervention: Two-level ACDF
Number of subjects: 599

Group type: COMPARATOR
Intervention: One-level ACDF
Number of subjects: 599
Study: 29372409

Group type: EXPERIMENTAL
Intervention: Solutions provided group
Number of subjects: 556

Group type: COMPARATOR
Intervention: Solutions withheld group
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 556
Study: 29372461

Group type: EXPERIMENTAL
Intervention: Irinotecan (135 mg/m²), oxaliplatin, and S-1 (OIS) regimen
Number of subjects: 44
Study: 29372860

Group type: EXPERIMENTAL
Intervention: Decompression with interlaminar stabilization (D+ILS)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Decompression alone (DA)
Number of subjects: 230
Study: 29373071

Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg once per day until disease progression
Number of subjects: 118
Study: 29373602

Group type: COMPARATOR
Intervention: 5 mg BID apixaban
Number of subjects: 37827

Group type: COMPARATOR
Intervention: 2.5 mg BID apixaban
Number of subjects: 37827
Study: 29373701

Group type: EXPERIMENTAL
Intervention: Etanercept treatment
Number of subjects: 75
Study: 29373711

Group type: EXPERIMENTAL
Intervention: Pioglitazone therapy for 24 weeks
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Post-pioglitazone follow-up
Number of subjects: 1
Study: 29373756

Group type: EXPERIMENTAL
Intervention: Antipsychotic-naïve patients
Number of subjects: 47
Study: 29373977

Group type: EXPERIMENTAL
Intervention: Thrombocytosis (platelet count ≥350 × 10^9/L)
Number of subjects: 4005
Study: 29373984

Group type: EXPERIMENTAL
Intervention: 12-week progressive, strength and neuromuscular exercise group (SNG) with supervised training twice weekly
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control intervention (CON) consisting of a home-based, low-intensity exercise program
Number of subjects: 50
Study: 29373989

Group type: EXPERIMENTAL
Intervention: Bifidobacterium
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Berberine
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Bifidobacterium combined berberine
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 300
Study: 29373993

Group type: EXPERIMENTAL
Intervention: Brief Behavioral Treatment for Insomnia (BBTI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia (CBTI)
Number of subjects: 0
Study: 29373998

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (laser group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Light-emitting diode (LED) therapy (LED group)
Number of subjects: 80
Study: 29374048

Group type: EXPERIMENTAL
Intervention: Arachidonic acid levels in AAA patients
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Omega-3 index levels in AAA patients
Number of subjects: 498

Group type: COMPARATOR
Intervention: Control group (age-matched controls)
Number of subjects: 498
Study: 29374101

Group type: EXPERIMENTAL
Intervention: White matter hyperintensities (WMH)
Number of subjects: 118
Study: 29374934

Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon pump application
Number of subjects: 0
Study: 29375477

Group type: EXPERIMENTAL
Intervention: Liquid formulation of r-hFSH/r-hLH (900/450 IU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Freeze-dried formulation of r-hFSH/r-hLH (900/450 IU)
Number of subjects: 0
Study: 29377059

Group type: EXPERIMENTAL
Intervention: Machine-learning models applied to regional grey matter
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Machine-learning models applied to whole-brain grey matter
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Computer-based classification
Number of subjects: 216
Study: 29377378

Group type: EXPERIMENTAL
Intervention: Multimodal, tailored, direct-to-patient, video intervention
Number of subjects: 2684

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2684

Group type: EXPERIMENTAL
Intervention: Multimodal, tailored, direct-to-patient, video intervention (n=257)
Number of subjects: 2684
Study: 29377566

Group type: EXPERIMENTAL
Intervention: Ribavirin dose adjustments
Number of subjects: 1548

Group type: EXPERIMENTAL
Intervention: Ribavirin dose reductions
Number of subjects: 1548

Group type: EXPERIMENTAL
Intervention: Low baseline haemoglobin
Number of subjects: 1548
Study: 29377748

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (650 mg EPA and 350 mg DHA daily)
Number of subjects: 11